Plasma prostacyclin levels in Behçet's disease. 1985

J M Ritter, and S E Barrow, and C Quigley

UI MeSH Term Description Entries
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001528 Behcet Syndrome Rare chronic inflammatory disease involving the small blood vessels. It is of unknown etiology and characterized by mucocutaneous ulceration in the mouth and genital region and uveitis with hypopyon. The neuro-ocular form may cause blindness and death. SYNOVITIS; THROMBOPHLEBITIS; gastrointestinal ulcerations; RETINAL VASCULITIS; and OPTIC ATROPHY may occur as well. Behcet Disease,Behcet's Disease,Behcet's Syndrome,Triple-Symptom Complex,Adamantiades-Behcet Disease,Behcet Triple Symptom Complex,Behçet Disease,Old Silk Route Disease,Triple Symptom Complex,Adamantiades Behcet Disease,Adamantiades-Behcet Diseases,Behçet Diseases,Symptom Complex, Triple,Triple Symptom Complices
D015121 6-Ketoprostaglandin F1 alpha The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue. 6-Keto-PGF1 alpha,6-Oxo-PGF1 alpha,6-Oxoprostaglandin F1 alpha,6 Ketoprostaglandin F1 alpha,6 Keto PGF1 alpha,6 Oxo PGF1 alpha,6 Oxoprostaglandin F1 alpha,F1 alpha, 6-Ketoprostaglandin,F1 alpha, 6-Oxoprostaglandin,alpha, 6-Keto-PGF1,alpha, 6-Ketoprostaglandin F1,alpha, 6-Oxo-PGF1,alpha, 6-Oxoprostaglandin F1

Related Publications

J M Ritter, and S E Barrow, and C Quigley
June 1985, Lancet (London, England),
J M Ritter, and S E Barrow, and C Quigley
January 1997, Clinical rheumatology,
J M Ritter, and S E Barrow, and C Quigley
May 2003, Rheumatology international,
J M Ritter, and S E Barrow, and C Quigley
February 1998, The Journal of rheumatology,
J M Ritter, and S E Barrow, and C Quigley
November 1997, Clinical rheumatology,
J M Ritter, and S E Barrow, and C Quigley
January 2000, Dermatology (Basel, Switzerland),
J M Ritter, and S E Barrow, and C Quigley
November 1986, Lancet (London, England),
J M Ritter, and S E Barrow, and C Quigley
January 2007, The Journal of dermatological treatment,
J M Ritter, and S E Barrow, and C Quigley
April 2012, Journal of the neurological sciences,
J M Ritter, and S E Barrow, and C Quigley
January 2000, Japanese journal of ophthalmology,
Copied contents to your clipboard!